Synthesis and biological evaluation of benzyloxymethyl-substituted imidazo[1,2-a]pyridines as apoptosis-inducing anticancer agents through modulation of BCL-2/Bax signaling and caspase-3 activation
Ege Arzuk, İbrahim Pinar, Burak Kuzu · 2026
Read Synthesis and biological evaluation of benzyloxymethyl-substituted imidazo[1,2-a]pyridines as apoptosis-inducing anticancer agents through modulation of BCL-2/Bax signaling and caspase-3 activation by Ege Arzuk, İbrahim Pinar, Burak Kuzu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13593677.txt.
Description
Ege Arzuk, İbrahim Pinar, and Burak Kuzu designed and built a new family of fourteen candidate anticancer compounds based on an imidazopyridine scaffold with a benzyloxymethyl group attached. In their 2026 study the compounds were checked with detailed chemical analysis, then tested against five human cancer cell lines.
Lung cancer and triple-negative breast cancer cells proved most sensitive. One compound, IPO9, stood out, killing lung cancer cells at a low dose while sparing normal cells far better, a pattern the team calls a favorable selectivity profile. The active compounds pushed cancer cells into programmed death by lowering the protective BCL-2 protein, raising its opponent Bax, damaging the cell's energy centers, and switching on caspase-3, an executioner enzyme. Computer docking placed IPO9 neatly in the BCL-2 binding pocket, supporting the laboratory picture.
Catalog record
| CREATOR | Ege Arzuk, İbrahim Pinar, Burak Kuzu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74220 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |